Q3 Earnings Estimate for DYN Issued By Lifesci Capital

Key Points

• Analysts at Lifesci Capital expect Dyne Therapeutics to report a Q3 2025 earnings per share (EPS) of ($0.80), maintaining a "Strong-Buy" rating on the stock.
• The consensus estimate for Dyne Therapeutics' full-year 2025 earnings has dropped to ($3.62) EPS, reflecting ongoing concerns about profitability.
• Overall, the stock is rated as a "Moderate Buy" by analysts, with a consensus target price of $34.07 despite recent price target reductions by several firms.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Equities research analysts at Lifesci Capital issued their Q3 2025 earnings per share (EPS) estimates for shares of Dyne Therapeutics in a report released on Tuesday, October 14th. Lifesci Capital analyst F. Brisebois expects that the company will post earnings of ($0.80) per share for the quarter. Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Dyne Therapeutics' current full-year earnings is ($3.44) per share. Lifesci Capital also issued estimates for Dyne Therapeutics' Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.62) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($3.55) EPS.

A number of other analysts have also issued reports on the company. Guggenheim reiterated a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Robert W. Baird decreased their price target on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research report on Wednesday, June 18th. Royal Bank Of Canada cut their price objective on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a research report on Tuesday, July 29th. Evercore ISI reaffirmed an "outperform" rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Finally, JPMorgan Chase & Co. cut their price target on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a report on Tuesday, July 15th. Four analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $34.07.

Dyne Therapeutics Price Performance

DYN opened at $16.53 on Thursday. The firm has a 50-day moving average price of $13.11 and a 200-day moving average price of $11.34. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $35.90. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -4.28 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02.

Insider Buying and Selling

In other news, CEO John Cox sold 2,640 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $13.41, for a total transaction of $35,402.40. Following the completion of the transaction, the chief executive officer directly owned 199,539 shares in the company, valued at approximately $2,675,817.99. This trade represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 14.14% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently made changes to their positions in DYN. GAMMA Investing LLC boosted its stake in Dyne Therapeutics by 837.5% during the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after purchasing an additional 2,345 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Dyne Therapeutics by 4.2% during the first quarter. Rhumbline Advisers now owns 133,627 shares of the company's stock valued at $1,398,000 after buying an additional 5,383 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Dyne Therapeutics by 5.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock worth $237,000 after buying an additional 1,115 shares in the last quarter. Arizona State Retirement System raised its position in Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock worth $183,000 after buying an additional 1,481 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its stake in Dyne Therapeutics by 725.8% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 80,665 shares of the company's stock valued at $844,000 after acquiring an additional 70,897 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.